Cingulate Inc. entered into a Note Purchase Agreement with Streeterville Capital, issuing a $5.48 million unsecured promissory note at 9% interest, maturing in 18 months, to fund working capital and operations. The company expects to have enough cash to support activities into Q4 2025 and plans to file for FDA approval of CTx-1301 by mid-2025.